Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lesinurad

FDA-approved product (tablet, oral), marketed as Zurampic.

Registered studies
22
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lesinurad
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Gout
  • Hyperuricemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Preparations increasing uric acid excretion
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

22registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lesinurad in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lesinurad with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Post-Authorisation Safety Study of Lesinurad

    NCT04072471 · start 2021-01-29

    Registered record
    Registry ID
    NCT04072471
    Conditions
    Gout; Hyperuricemia
    Interventions
    Zurampic®; Control group: xanthine oxidase inhibitor monotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2021-01-29
    Completion
    2023-06-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout; Hyperuricemia
    InterventionZurampic®; Control group: xanthine oxidase inhibitor monotherapy
    PhaseNot recorded
    Registry statusWithdrawn

  • Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

    NCT03272425 · start 2017-08-14

    Registered record
    Registry ID
    NCT03272425
    Conditions
    Gout
    Interventions
    lesinurad/allopurinol 200/300 FDC tablets; lesinurad 200 mg; allopurinol 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-08-14
    Completion
    2017-10-04
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    Interventionlesinurad/allopurinol 200/300 FDC tablets; lesinurad 200 mg; allopurinol 300 mg
    PhasePhase 1
    Registry statusCompleted

  • A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

    NCT03226899 · start 2017-07-19

    Registered record
    Registry ID
    NCT03226899
    Conditions
    Gout; Chronic Kidney Disease (CKD)
    Interventions
    Lesinurad; XOI; Placebo; colchicine; corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-07-19
    Completion
    2019-02-25
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout; Chronic Kidney Disease (CKD)
    InterventionLesinurad; XOI; Placebo; colchicine +1 more
    PhasePhase 4
    Registry statusTerminated

  • Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

    NCT02888054 · start 2016-08-30

    Registered record
    Registry ID
    NCT02888054
    Conditions
    Healthy
    Interventions
    lesinurad/allopurinol 200/300 FDC tablet; lesinurad 200 mg; allopurinol 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-08-30
    Completion
    2017-02-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionlesinurad/allopurinol 200/300 FDC tablet; lesinurad 200 mg; allopurinol 300 mg
    PhasePhase 1
    Registry statusCompleted

  • Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

    NCT02581553 · start 2015-10

    Registered record
    Registry ID
    NCT02581553
    Conditions
    Healthy
    Interventions
    lesinurad/allopurinol 200/300 FDC tablets; lesinurad 200 mg; allopurinol 300 mg; lesinurad/allopurinol 200/200 FDC tablets; allopurinol 200 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-10
    Completion
    2016-08
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionlesinurad/allopurinol 200/300 FDC tablets; lesinurad 200 mg; allopurinol 300 mg; lesinurad/allopurinol 200/200 FDC tablets +1 more
    PhasePhase 1
    Registry statusCompleted

  • Lesinurad Tablet Bioequivalence

    NCT02127775 · start 2014-04

    Registered record
    Registry ID
    NCT02127775
    Conditions
    Healthy
    Interventions
    Lesinurad 400 mg (manufactured at Site 1); Lesinurad 400 mg (manufactured at Site 2)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2014-07
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLesinurad 400 mg (manufactured at Site 1); Lesinurad 400 mg (manufactured at Site 2)
    PhasePhase 1
    Registry statusCompleted

  • Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

    NCT02039700 · start 2014-01

    Registered record
    Registry ID
    NCT02039700
    Conditions
    Healthy
    Interventions
    Lesinurad 400 mg; [14C]lesinurad (100 μg per 10 mL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-01
    Completion
    2014-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLesinurad 400 mg; [14C]lesinurad (100 μg per 10 mL)
    PhasePhase 1
    Registry statusCompleted

  • Antacid Interaction Study

    NCT01982201 · start 2013-11

    Registered record
    Registry ID
    NCT01982201
    Conditions
    Healthy
    Interventions
    Lesinurad 400 mg; Tums 500 mg and 750 mg; MINTOX 10 mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-11
    Completion
    2014-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLesinurad 400 mg; Tums 500 mg and 750 mg; MINTOX 10 mL
    PhasePhase 1
    Registry statusCompleted

  • Lesinurad Tablet Relative Bioavailability

    NCT01986556 · start 2013-11

    Registered record
    Registry ID
    NCT01986556
    Conditions
    Healthy
    Interventions
    Lesinurad 400 mg (Site 1); Lesinurad 400 mg (Site 2, Lot A); Lesinurad 400 mg (Site 2, Lot B)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-11
    Completion
    2014-05
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLesinurad 400 mg (Site 1); Lesinurad 400 mg (Site 2, Lot A); Lesinurad 400 mg (Site 2, Lot B)
    PhasePhase 1
    Registry statusCompleted

  • Metformin and Furosemide Drug-Drug Interaction Study

    NCT02028689 · start 2013-10

    Registered record
    Registry ID
    NCT02028689
    Conditions
    Healthy
    Interventions
    Lesinurad 400 mg; Metformin 850 mg; Furosemide 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLesinurad 400 mg; Metformin 850 mg; Furosemide 40 mg
    PhasePhase 1
    Registry statusCompleted

  • Lesinurad Interaction Study With Ranitidine

    NCT01908257 · start 2013-07

    Registered record
    Registry ID
    NCT01908257
    Conditions
    Healthy
    Interventions
    lesinurad 400 mg; ranitidine 150 mg; lesinurad 400 mg + ranitidine 150 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-07
    Completion
    2013-11
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionlesinurad 400 mg; ranitidine 150 mg; lesinurad 400 mg + ranitidine 150 mg
    PhasePhase 1
    Registry statusCompleted

  • NSAID Drug Interaction Study

    NCT01884272 · start 2013-06

    Registered record
    Registry ID
    NCT01884272
    Conditions
    Gout
    Interventions
    lesinurad 400 mg; naproxen 250 mg; indomethacin 25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06
    Completion
    2013-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    Interventionlesinurad 400 mg; naproxen 250 mg; indomethacin 25 mg
    PhasePhase 1
    Registry statusCompleted

  • Lesinurad and Febuxostat Combination Extension Study in Gout

    NCT01808144 · start 2013-03-01

    Registered record
    Registry ID
    NCT01808144
    Conditions
    Gout
    Interventions
    lesinurad; lesinurad; febuxostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03-01
    Completion
    2016-10-06
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    Interventionlesinurad; lesinurad; febuxostat
    PhasePhase 3
    Registry statusCompleted

  • Lesinurad and Allopurinol Combination Extension Study in Gout

    NCT01808131 · start 2013-02

    Registered record
    Registry ID
    NCT01808131
    Conditions
    Gout
    Interventions
    Lesinurad; Lesinurad
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-02
    Completion
    2016-11
    Enrolment
    717

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionLesinurad; Lesinurad
    PhasePhase 3
    Registry statusCompleted

  • Single and Multiple Dose Study in Japanese

    NCT01744379 · start 2012-12

    Registered record
    Registry ID
    NCT01744379
    Conditions
    Gout
    Interventions
    Lesinurad; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionLesinurad; Placebo
    PhasePhase 1
    Registry statusCompleted